1	Acute	respiratory
1	respiratory	distress
1	distress	syndrome
1	syndrome	(ARDS
1	(ARDS	)
2	)	and
1	and	acute
1	acute	lung
1	lung	injury
1	injury	(ALI
1	(ALI	)
1	)	are
1	are	conditions
1	conditions	associated
2	associated	with
1	with	an
1	an	estimated
1	estimated	mortality
1	mortality	of
1	of	40–50%
1	40–50%	.
1	.	The
1	The	use
2	use	of
2	of	inhaled
1	inhaled	vasodilators
1	vasodilators	can
1	can	help
1	help	to
1	to	improve
2	improve	oxygenation
1	oxygenation	without
1	without	hemodynamic
1	hemodynamic	effects
1	effects	.
1	.	This
1	This	article
1	article	reviews
1	reviews	relevant
1	relevant	studies
1	studies	addressing
1	addressing	the
1	the	safety
1	safety	and
1	and	efficacy
1	efficacy	of
2	of	inhaled
1	inhaled	nitric
1	nitric	oxide
1	oxide	(iNO
1	(iNO	)
2	)	and
1	and	aerosolized
1	aerosolized	epoprostenol
1	epoprostenol	(aEPO
1	(aEPO	)
1	)	in
1	in	the
1	the	treatment
1	treatment	of
1	of	life-threatening
1	life-threatening	hypoxemia
1	hypoxemia	associated
2	associated	with
1	with	ARDS
1	ARDS	and
1	and	ALI
1	ALI	.
1	.	In
1	In	addition
1	addition	,
2	,	the
1	the	article
1	article	also
1	also	provides
1	provides	a
1	a	practicable
1	practicable	guide
1	guide	to
1	to	the
1	the	clinical
1	clinical	application
1	application	of
1	of	these
1	these	therapies
1	therapies	.
1	.	Nine
1	Nine	prospective
1	prospective	randomized
1	randomized	controlled
1	controlled	trials
1	trials	were
1	were	included
1	included	for
1	for	iNO
1	iNO	reporting
1	reporting	on
1	on	changes
2	changes	in
2	in	oxygenation
1	oxygenation	or
1	or	clinical
1	clinical	outcomes
1	outcomes	.
1	.	Seven
1	Seven	reports
1	reports	of
1	of	aEPO
1	aEPO	were
1	were	examined
1	examined	for
1	for	changes
2	changes	in
2	in	oxygenation
2	oxygenation	.
1	.	Based
1	Based	on
1	on	currently
1	currently	available
1	available	data
1	data	,
2	,	the
1	the	use
2	use	of
1	of	either
1	either	iNO
2	iNO	or
2	or	aEPO
1	aEPO	is
1	is	safe
1	safe	to
1	to	use
1	use	in
1	in	patients
1	patients	with
1	with	ALI
1	ALI	or
1	or	ARDS
1	ARDS	to
1	to	transiently
1	transiently	improve
2	improve	oxygenation
2	oxygenation	.
1	.	No
1	No	differences
1	differences	have
1	have	been
1	been	observed
1	observed	in
1	in	survival
1	survival	,
1	,	ventilator-free
1	ventilator-free	days
1	days	,
1	,	or
1	or	attenuation
1	attenuation	in
1	in	disease
1	disease	severity
1	severity	.
1	.	Further
1	Further	studies
1	studies	with
1	with	consistent
1	consistent	end
1	end	points
1	points	using
1	using	standard
1	standard	delivery
1	delivery	devices
1	devices	and
1	and	standard
1	standard	modes
1	modes	of
1	of	mechanical
1	mechanical	ventilation
1	ventilation	are
1	are	needed
1	needed	to
1	to	determine
1	determine	the
1	the	overall
1	overall	benefit
1	benefit	with
1	with	iNO
2	iNO	or
2	or	aEPO
1	aEPO	.
